Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: Facts or fancies?

European Journal of Internal Medicine

Volumn 21, Issue 6, 2010, Pages 484-489

  Lettino, Maddalena ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Acute coronary syndrome; Clopidogrel; Dual antiplatelet therapy; Percutaneous coronary intervention; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; BENZIMIDAZOLE DERIVATIVE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; RABEPRAZOLE; THIENOPYRIDINE DERIVATIVE; THIOL DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; ARTERY DISEASE; BARE METAL STENT; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE PERSONNEL; HEART INFARCTION; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 78649522126     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.08.004     Document Type: Short Survey

References (37)

1. M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagibara, N.A. Farid, and O. Okazaki Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
2. CAPRIE Steering Committee A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) Lancet 348 1996 1329 1339
3. P.A. Gurbel, and U.S. Tantry Combination antithrombotic therapies Circulation 121 2010 569 583
4. M.E. Bertrand, H.J. Rupprecht, P. Urban for the CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent Interventional Cooperative Study Circulation 102 2000 624 629
5. -2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to review new evidence and update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention Writing on behalf of the 2005 Writing Committee Circulation 117 2008 261 295
6. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicious, G. Tognoni, K.K. Fox for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation New Engl J Med 345 2001 494 502
7. M.E. Bertrand, M.L. Simoons, K.A.A. Fox, L.C. Wallentin, C.W. Hamm, E. McFadden on behalf of the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology Management of acute coronary syndromes in patients presenting without persistent ST-elevation Eur Heart J 23 2002 1809 1840
8. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. Lopez-Sendon, G. Montalescot, P. Theroux CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation New Engl J Med 352 2005 1179 1189
9. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial Lancet 366 2005 1607 1621
10. F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology Management of Acute Myocardial Infarction in patients presenting with persistent ST-segment elevation Eur Heart J 29 2008 2909 2945
11. J.M. Shin, Y.M. Choo, and G. Sachs Chemistry of covalent inhibition of the gastric (H+/K+)-ATPase by proton pump inhibitors J Am Chem Soc 126 2004 7800 7811
12. X.Q. Li, T.B. Andersson, M. Ahlström, and L. Weidolf Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on humans Cytochrome P450 activities Drug Metab Disp 32 2004 821 827
13. S. Shi, and U. Klotz Proton pump inhibitors: an update of their clinical use and pharmacokinetics Eur J Clin Pharmacol 64 2008 935 951
14. K.M. Fock, T.L. Ang, L.C. Bee, and E.J. Deon Lee Proton pump inhibitors. Do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 47 1 2008 1 6
15. P. Miner, P.O. Katz, Y.S. Chen, and M. Sostek Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study Am J Gastroenetrol 98 2003 2616 2620
16. K.R. McQuaid, and L. Laine Systemic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials Am J Med 119 2006 624 638
17. A. Lanas, and J. Sheiman Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment Curr Med Res Opin 23 2007 163 173
18. L. Ma, S.N. Elliott, G. Cirino, A. Buret, L.J. Ignarro, and J.L. Wallace Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release Procl Nat Acad Sci U S A. 98 2001 6470 6475
19. K. Barada, W. Karrowni, M. Abdallah, W. Shamseddeen, A.I. Sharara, and H.A. Dakik Upper gastrointestinal bleeding in patients with acute coronary syndromes. Clinical predictors and prophylactic role of proton pump inhibitors J Clin Gastroenterol 42 2008 368 372
20. Bhatt DL. COGENT: a prospective, plecebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, 24 September 2009. San Francisco, CA.
21. D.L. Bhatt, J. Sheiman, N.S. Abraham, E.M. Antman, F.K.L. Chan, and C.D. Furberg ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology task force on clinical expert consensus documents Circulation 118 2008 1894 1909
22. H. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin JACC 51 2008 256 260
23. T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, and L. Bali Comparison of omeprazole and pantoprazole influence on high 150-mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective, randomized study JACC 54 2009 1149 1153
24. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 2009 148.e1 148.e5
25. D. Sibbing, T. Morath, J. Stegherr, S. Braun, W. Vogt, and M. Hadamitzky Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 2009 714 719
26. M.L. O'Donoghue, E. Braunwald, E.M. Antman, S.A. Murphy, E.R. Bates, and Y. Rozenman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials Lancet 374 2009 989 997
27. D.N. Juurlink, T. Gomes, D.T. Ko, P.E. Szmitko, P.C. Austin, and J.V. Tu A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 7 2009 713 718
28. P.M. Ho, T.M. Maddox, L. Wang, D.S. Fihm, R.L. Jesse, E.D. Peterson, and G.S. Rumsfeld Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 9 2009 937 944
29. C.S. Kwok, and Y.K. Loke Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol Ther 87 1 2010 32 36
30. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, and O. Barthelemy Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration A systematic meta-analysis. JACC 56 2010 134 143
31. U.S. Food and Drug Administration. Public Health Advisory: updated safety information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec or Prilosec OTC). 17 November 2009. http//www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm
32. European Medicine Agency. Public statement of interaction between clopidogrel and proton pump inhibitors. 17 March 2010. http//www.emea.europa.eu/ ema/index.jsp?curl=pages/news-and-events/news/2010/03/news-detail-001008. jsp&mid.=WC0b01ac058004d5
33. A. Shömig Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med 361 2009 1108 1111
34. M. Franchini, and P.M. Mannucci New antiplatelet agents: why they are needed Eur J Int Med 20 2009 733 738
35. K.M. Stockl, A. Zakharyan, A.S.M. Harada, B.K. Solow, J.E. Addiego, and S. Ramsey Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor Arch Intern Med 107 8 2010 704 710
36. J.A. Rassen, N.K. Choudhry, J. Avorn, and S. Schneeweiss Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2009 2322 2329
37. W.A. Ray, K.T. Murray, M.R. Griffin, C.P. Chung, W.E. Smalley, and K. Hall Outcomes with concurrent use of clopidogrel and proton-pump inhibitors Ann Intern Med 152 2010 337 345